Skip to main content
Hauptrubriken
Zeitschriften Fortbildung Hebammen Bücher Kongresse & Live-Webinare
Social Media - Folgen Sie uns!
Instagram Facebook LinkedIn Instagram Hebammen
Service
Jobbörse Kundenservice Info & Hilfe
Fokus-Themen
Chronisch-entzündliche Darmerkrankung COVID-19-Update Diabetes Hautpflege Klima & Gesundheit Hygiene Intensivpflege Kardiologische Pflege Mobilisation Nachhaltigkeit Nierenerkrankungen Obstipation Onkologische Pflege Palliativpflege Schmerz Sucht in der Pflege Vielfalt, Gleichberechtigung und Inklusion Wundversorgung
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Kapitel lesen Erstes Kapitel lesen

2016 | OriginalPaper | Buchkapitel

22. Hypertensive Schwangerschaftserkrankungen

verfasst von : Luigi Raio, Marc Baumann, Henning Schneider

Erschienen in: Die Geburtshilfe

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hypertensive Erkrankungen gehören mit ihren verschiedenen klinischen Ausprägungen und Manifestationsarten zu den häufigsten Komplikationen in der Schwangerschaft, und in den industrialisierten Ländern bleibt die Präeklampsie einer der wichtigsten Gründe für die maternale Mortalität. Die meisten Fachgesellschaften fokussieren auf die verschiedenen Hypertoniemanifestationen in der Schwangerschaft als zentrales Kriterium für die Klassifizierung.
Die Prädiktion der Präeklampsie und anderer plazentagebundener Schwangerschaftserkrankungen wurde verfeinert. Die Kombination von Angiogenesefaktoren zusammen mit Anamnese bzw. bestehenden Risikofaktoren, der Dopplersonographie der Aa. uterinae und gewissen klinischen Daten hat die Risikostratifizierung wesentlich verbessert. Nach wie vor ist die einzige kausale Therapie der Präeklampsie die Entbindung. Auch ein Zusammenhang zwischen Präeklampsie und dem späteren Auftreten mütterlicher kardiovaskulärer Erkrankungen gilt als erwiesen.
Vorheriges Kapitel Physiologie des mütterlichen Organismus und Erkrankungen in der Schwangerschaft
Nächstes Kapitel Anämie in der Schwangerschaft
Literatur
Abalos E, Duley L, Steyn D, Henderson-Smart D (2007) Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev CD002252
Abildgaard U, Heimdal K (2013) Pathogenesis of the hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 166:117–123PubMedCrossRef
ACOG (2001) Practice Bulletin. Chronic hypertension in pregnancy. ACOG committee on practice bulletins. Obstet Gynecol. 98(Suppl 1):177–185
ACOG (2002) practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. ACOG committee on practice bulletins-obstetrics. Obstet Gynecol. 99(1):159–167
ACOG (2013) Committee opinion 573. Magnesium sulfate use in obstetrics. Obstet Gynecol 122(3):727–728CrossRef
ACOG Comittee Opinion 211 (1998) Anticoagulation with low molecular weight heparin during pregnancy. Washington, DC
Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884–891PubMedCrossRef
Ahmed A (1997) Heparin-binding angiogenic growth factors in pregnancy. Trophoblast Res 10(215):258
Alexander JM, McIntire DD, Levenko KJ, Cunningham FG (2006) Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol 108(4):826–832PubMedCrossRef
Alkan A, Tugrul S, Oral O, Uslu H, Köse D, Catakli FT (2006) Effects of postpartum uterine curettage on maternal wellbeing in severe preeclamptic patients. Clin Exp Obstet Gynecol 33:55–58PubMed
Anderson UO, Olsson MG, Ruttardotir S, Centlow M, Kristensen KH, Isberg PE, Thilaganathan B, Akerström B, Hansson SR (2011) Fetal hemoglobin and α1 – macroglobulin as first- and early second-trimester predictive biomarker for preeclampsia. Am J Obstet Gynecol 204:520.e1–520.e5CrossRef
Ascarelli MH, Johnson V, McCreary H et al (2005) Postpartum preeclampsia management with Furosemid: a randomized clinical trial. Obstet Gynecol 105:29–33PubMedCrossRef
Askie LM, Duley L, Henderson-Smart D, Stewart LA, on behalf of the PARIS collabborative group (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369:1791–1798PubMedCrossRef
Assali NS, Kaplan S, Oighenstein S, Suyemoto R (1953) Hemodynamic effect of l-hydracinophthalazine in human pregnancy; results of intravensous administration. J Clin Invest 32:922–933PubMedPubMedCentralCrossRef
Atkinson MW, Belfort MA, Saade GR, Moise KJ (1994) The relation between magnesium sulfate therapy and fetal heart rate variability. Obstet Gynecol 83:967–970PubMedCrossRef
AWMF-Leitlinien-Register Nr.015/018 Diagnostik und Therapie hypertensiver Schwangeschaftserkrankungen. Überarbeitung vom Mai 2008
Ayuk PT, Matijevic R (2006) Placental ischaemia is a consquence rather than cause of preeclampsia. Med Hypotheses 67:792–795PubMedCrossRef
Barron WM, Heckerling P, Hibbard JU, Fisher S (1999) Reducing unneccessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol 94:364–370PubMed
Barton JR, Sibai BM (1996) Hepatic imaging in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets count). Am J Obstet Gynecol 174:1820–1825PubMedCrossRef
Barton JR, Sibai BM (2008) Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 112:359–372PubMedCrossRef
Barton JR, O´Brian JM, Bergauer NK et al (2001) Mild gestational hypertension remote from term: progession and outcome. Am J Obstet Gynecol 184:979–983PubMedCrossRef
Baschat AA, Gembruch U, Harman CR (2001) The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 18:581–577
Bates SM, Greer IA, Papinger I, Shoshana S, Hirsch J (2008) Venous thromboembolism, thrombophila, antithrombotic therapie, and pregnancy. Chest 133:844–886CrossRef
Baumann MU, Bersinger NA, Surbek DV (2007) Serum markers for predicting pre-eclampsia. Mol Asp Med 28:227–244CrossRef
Baumann MU, Bersinger NA, Mohaupt MG et al (2008) First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 199:266.e1–266.e6CrossRef
Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM (2005) Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 192(2):520–521PubMedCrossRef
Belfort MA, Moise KJ (1992) Effect of magnesiumsulfate on maternal brain blood flow in preeclampsia: a randomized placebo-controlled study. Am J Obstet Gynecol 167:661–666PubMedCrossRef
Belfort MA, Clark SL, Sibai B (2006) Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate. Obstet Gynecol Surv 61:655–665PubMedCrossRef
Belizan JM, Villar J, Gonzalez L, Campodonica L, Bergel E (1991) Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 325:1399–1405PubMedCrossRef
Bellomo G, Narducci PL, Randoni F et al (1999) Prognostic value of 24-hour blood pressure in pregnancy. JAMA 282:1447–1452PubMedCrossRef
Bombrys AE, Barton JR, Nowacki EA, Habli M, Pinder L, How H, Sibai BM (2008a) Expectant management of severe preeclampsia at less than 27 weeks’ gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 199:247.e1–247.e6CrossRef
Bombrys AE, Barton JR, Nowacki EA, Habil M, Pinder L, How H et al (2008b) Expectant management odf severe preeclampsia at less than 27 weeks’ gestation. Am J Obstet Gynecol 199:247e1–247e6CrossRef
Bosio PM, McKenna PJ, Conroy R, O´Herlihy C (1999) Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 94:978–984PubMed
Broekenhuizen FF, Elejalde R, Hamilton RR (1983) Early onset preeclampsia, triploidy and fetal hydrops. J Reprod Med 28:223–226
Brown MA, Mangos G, Davis G, Homer C (2005a) The natural history of white coat hypertension during pregnancy. BJOG 112(5):601–606PubMedCrossRef
Brown MA, Mangos G, Davis G, Homer C (2005b) The natural history of white coat hypertension during pregnancy. BJOG 112(5):601–606PubMedCrossRef
Bucher HC, Guyatt GH, Cook RJ, Hatala R, Cook DJ, Lang JD, Hunt D (1996) Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized trials. J Am Med Assoc 275:1113–1117CrossRef
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S et al (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116(2 Pt 1):402–414PubMedCrossRef
Burton GJ, Woods AW, Jauniaux E, Kingdom JC (2009) Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30:473–482PubMedPubMedCentralCrossRef
Butters L, Kennedy S, Rubin PC (1990) Atenolol in essential hypertension during pregnancy. Br Med J 301:587CrossRef
Centre for Maternal and Child Enquiries (CMACE) (2011) Saving Mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–08. The eighth report on confidential enquiries into maternal deaths in the United Kingdom. BJOG 118(Suppl 1):1–203
Chames MC, Haddad B, Barton RJ et al (2003) Subsequent pregnancy outcome in women with a history of Hellp syndrome at ≤28 weeks of gestation. Am J Obstet Gynecol 188:1504–1507PubMedCrossRef
Chang EY, Menard MK, Vermillion ST et al (2004) The association between hyaline membrane disease and preeclampsia. Am J Obstet Gynecol 191:1414–1417PubMedCrossRef
Chappell LC, Duckworth D, Seed PT, Griffin M, Myers J, Mackillop L et al (2013) Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 128:2121–2131PubMedCrossRef
CLASP (Collaborative low-dose Aspirin study in pregnancy) Collabrative group (1994) CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 105:619–629
Cnossen JS, Vollebregt KC, de Virenze N, Riet ter G, Mol BWJ et al (2009) Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia:systemic review and meta-analysis. BMJ 336:1117–1120CrossRef
Cockburn J, Moar VA, Ounsted M, Redman CW (1982) Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1:647–649PubMedCrossRef
Cook HW, Briggs JC (1903) Clinical observations on blood pressure. Johns Hopkins Hosp 11:451–455
Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Kathi H, Ray WA (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443–2451PubMedCrossRef
Coppage KH, Polzin WJ (2002) Severe preeclampsia and delivery outcomes: is immediate cesarean delivery beneficial? Am J Obstet Gynecol 186:921–923PubMedCrossRef
Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM (2015) Pregnancy-related mortality in the United States, 2006–2010. Obstet Gynecol 125(1):5–12PubMedCrossRef
Cudmore M, Ahmad S, Al-Ani B et al (2007) Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115:1789–1797PubMedCrossRef
Danza A, Ruiz-Irastorza G, Khamashta M (2012) Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol 26:65–76PubMedCrossRef
Dao V, Rodger M (2009) Anticoagulation to prevent placental-mediated pregnancy complication: a review of current evidence. Curr Opin Hematol 16(5):386–390, 22 [Epub ahead of print]PubMedCrossRef
Dashe JS, Ranin SM, Cinningham FG (1998) The long term consequences of thrombotic microangiopathy in pregnancy. Obstet Gynecol 91:662–668PubMed
Dekker G, Sibai BM (1993) Low dose aspirin in the prevention of preeclampsia and fetal growth retardation: rational mechanisms and clinical trials. Am J Obstet Gynecol 168:214–227PubMedCrossRef
Dekker G, Sibai BM (2001) Primary, secondary and tertiary prevention of preeclampsia. Lancet 357:207–215
Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn HP (1995) Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173:1042–1048PubMedCrossRef
Derks JB, Mulder EJH, Visser GHA (1995) The effects of maternal bethametasone administration on the fetus. Br J Obstet Gynaecol 102:40–46PubMedCrossRef
Deruelle P, Coudoux E, Ego A, Houfflin-Debarge V, Codaccioni X, Subtil D (2006) Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 125(1):59–65PubMedCrossRef
Duckitt K, Harrington B (2005) Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. Br Med J 330:565CrossRef
Duley L, Henderson-Smart D, Knight M, King J (2004) Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 1, CD004659PubMed
Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D (2010a) Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev (11):CD000025
Duley L, Henderson-Smart DJ, Chou D (2010b) Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev (10):CD000025
Duley L, Meher S, Johns L (2013) Drugs for treatment of very high blood pressure during pregnancy Cochrane Database Syst Rev 7:CD001449
Duvekot JJ, Cheriex EC, Pieters FA, Menheer PP, Peeters LH (1993) Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 169:1382–1392PubMedCrossRef
Eclampsia Trial Collaborative Group (1995) Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet 345:1455–1463CrossRef
Facchinetti F, Marozio L, Frusca T et al (2009) Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 200:46.e1–46.e5CrossRef
Fenakel K, Fenakel G, Appelman Z et al (1991) Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 77:331–337PubMed
Fonseca JF, Mendrez F, Catano C, Arias F (2005) Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 193:1591–1598PubMedCrossRef
Friedman SA, Schiff E, Kaa L, Sibai BM (1995) Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 172:1785–1792PubMedCrossRef
Galarza-Maldonado C, Kourilovitch MR, Pérez-Fernandez OM, Gaybor M, Cordero C et al (2012) Obstetric antiphospholipid syndrome. Autoimmun Rev 11:288–295PubMedCrossRef
Gangaram R, Ojwang PJ, Moodley J, Maharaj A (2005) The accuracy of urine dipsticks as a screening test for proteinuria in hypertensive disorders of pregnancy. Hypertens Pregnancy 24:96–101CrossRef
Genius SJ (2008) A fishy recommendation: omega-3 fatty acid intake in pregnancy. Br J Obstet Gynaecol 115:1–4CrossRef
Gennari-Moser C, Escher G, Kramer S, Dick B, Eisele N, Baumann M, Raio L, Frey FJ, Surbek D, Mohaupt MG (2013) Normotensive blood pressure in pregnancy: the role of salt and aldosterone. Hypertension (2). doi:10.1161
Goldenberg RL, Cliver SP, Bronstein J et al (1994) Bed rest in pregnancy. Obstet Gynecol 84:131–136PubMed
Goldman-Wohl D, Yagel S (2002) Regulation of trophoblast invasion: from normal implantation to preeclampsia. Mol Cell Endocrinol 187:233–238PubMedCrossRef
Gray SE, Rodis JF, Lettieri L, Egan JFX, Vintzileos A (1994) Effect of intravenous magnesium sulfate on the biophysical profile in the healthy preterm fetus. Am J Obstet Gynecol 170:1131–1135PubMedCrossRef
Greer IA, Walker JJ, McLaren M et al (1985a) A comparative study of the effect of adrenoreceptor antagonist on platelet aggregation and thromboxane generation. Thromb Haemost 54:480–484PubMed
Greer IA, Walker JJ, McLaren M et al (1985b) Inhibition of thromboxane and prostacyclin in whole blood by adrenoreceptor antagonists. Prostaglandins Leukot Med 19:209–217PubMedCrossRef
Gupta AK, Rusterholz C, Huppertz B et al (2005) A comparative study of the effect of three different syncytiotrophoblast micro-particle preparations on endothelial cells. Placenta 26:59–66PubMedCrossRef
Hall DR, Odendaal HJ, Steyn DW, Grevé D (2000) Expectant management of early onset, severe preeclampsia maternal outcome. Br J Obstet Gynaecol 107:1252–1257CrossRef
Hansson SR, Gram M, Akerström B (2013) Fetal hemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy. Curr Opin Obstet Gynecol 25:448–455PubMedCrossRef
Hauth JC, Ewell MG, Levine RL, Esterlitz JR, Sibai BM, Curet LB (2000) Pregnancy outcomes in health nulliparous women who subsequently developed hypertension: calcium for preeclampsia prevention study group. Obstet Gynecol 95:24–28PubMed
Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackelöer BJ, Kok HJ, Senat MV, Visser GHA (2001) Monitoring fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 18:564–570PubMedCrossRef
Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, Golding J (2007) Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): a observational cohort study. Lancet 369:578–585PubMedCrossRef
Higgins JR, de Swiet M (2001) Blood-pressure measurement and classification in pregnancy. Lancet 357:131–135PubMedCrossRef
Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, McPherson C et al (2002) Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 186:422–426PubMedCrossRef
Hoedjes M, Berks D, Vogel I, Franx A et al (2011) Poor health-related quality of life after severe preeclampsia. Birth 38(3):246–255PubMedCrossRef
Hofmeyer GJ, Duley L, Atallah A (2007) Dietary calcium supplementation for prevention pf pre-eclampsia and related problems: a systemic review and commentary. Br J Obstet Gynaecol 114:933–943CrossRef
Howie PW, Prentice CRM, Forbes CD (1975) Failure of heparin therapy to affect the clinical course of severe pre-eclampsia. Br J Obstet Gynaecol 82:711–717PubMedCrossRef
Hunter SK, Martin M, Benda JA, Zlatnik FJ (1995) Liver transplant after massive spontaneous hepatic rupture in pregnancy complicated by preeclampsia. Obstet Gynecol 85:819–822PubMedCrossRef
Huppertz B (2008) Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51:970–975PubMedCrossRef
Hüskes KP, Baumgartner A, Hardt U, Fink F (1991) Doppelseitige, mehrzeitige Spontanruptur der Leber bei HELLP-Syndrom. Chirurg 62:221–222PubMed
Impey L (1993) Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 100:959–961PubMedCrossRef
Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y (1993) Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 169:423–426PubMedCrossRef
Innes KE, Marshall JA, Byers TE, Calonge N (1999) A woman's own birth weight and gestational age predict her later risk of developing preeclampsia, a precursor of chronic disease. Epidemiology 10:791–792
Jankowicz D, Tuffnell DJ (2004) Managing pre-eclampsia 1: establishing guidelines. Br J Midwifery 12:35–40
Jenkins SM, Head BB, Hauth JC (2002) Severe preeclampsia at less than 25 weeks of gestation: maternal and neonatal outcomes. Am J Obstet Gynecol 186:790–795PubMedCrossRef
Jim B, Sharma S, Kebede T, Acharaya A (2010) Hypertension in pregnancy: a comprehensive update. Cardiol Rev 18(4):178–189PubMedCrossRef
JNC 7 (2004) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (August 2004). NIH Publication No. 04–5230
Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA (2010) Liver disease in pregnancy. Lancet 375:594–605PubMedCrossRef
Kahn SR, Platt R, McNamara H et al (2009) Inherited thrombophilia and preeclampsia within a multicenter cohort: the montreal preeclampsia study. Am J Obstet Gynecol 200(2):151.e1–151.e9, discussion e1–5CrossRef
Khalil A, Harrington K, Muttukrishna S, Jauniaux E (2010) Effect of antihypertensive therapy with alpha-methyldopa on uterine artery Doppler in pregnancies with hypertensive disorders. Ultrasound Obstet Gynecol 35:688–694PubMed
Knight M, Redman CW, Linton EA, Sargent JL (1998) Shedding of syncytrophoblast microvilli into the maternal circulation in preeclamptic pregnancies. Br J Obstet Gynaecol 105:632–640PubMedCrossRef
Kuklina EV, Ayala C, Callaghan WM (2009) Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 113(6):1299–1306PubMedCrossRef
Künzel W, Misselwitz B (2003) Unexpected fetal death during pregnancy – a problem of unrecognized fetal disorders during antenatal care? Eur J Obstet Gynecol Reprod Biol 110(Suppl 1):386–396
Kupferminc MJ, Eldor A, Steinman N et al (1999) Increased frequency of genetic thrombophilia. N Engl J Med 340:9–13PubMedCrossRef
Kweider N, Wruck CJ, Rath W (2013) New insights into the pathogenesis of preeclampsia – the role of Nrf2 activators and their potential therapeutic impact. Geburtshilfe Frauenheilkd 73:1236–1240PubMedPubMedCentralCrossRef
Lain KJ, Roberts JM (2002) Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 287:3183–3186PubMedCrossRef
Langenveld J, Jansen S, van der Post J, Wolf H et al (2010) Recurrence risk of a delivery before 34 weeks of pregnancy due to an early onset hypertensive disorder: a systemic review. Am J Perinatol 27:565–571PubMedCrossRef
Lees C, Marlow N, Arabin B, Bilardo CM, TRUFFLE Group et al (2013) Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol 42(4):400–408PubMedCrossRef
Levine RJ, Maynard SE, Quian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683PubMedCrossRef
Levine RJ, Thadhaini R, Quian C et al (2005) Urinary placental growth factor and risk of preeclampsia. JAMA 293:77–85PubMedCrossRef
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group (2006) Soluble endoglin and other circulating angiogenic factors in preeclampsia. N Engl J Med 355:992–1005PubMedCrossRef
Leviton A, Kuban KC, Pagano M et al (1993) Antenatal corticosteroids appear to reduce the risk of postnatal germinal matrix hemorrhage in intubated low birth weight newborns. Pediatrics 91:1083–1088PubMed
Levytska K, Kingdom J, Bacyk D et al (2013) Heme oxygenase-1 in placental development and pathology. Placenta 34:291–298PubMedCrossRef
Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data of 1 million adults in 61 perspective studies. Lancet 360:1903–1913PubMedCrossRef
Lewis G (Hrsg) (2007) The Confidential enquiry into maternal and child health (CEMACH). Saving mother’s lives: Reviewing maternal deaths to make motherhood safer 2003–2005. The seventh report. RCOG Press, London
Li H, Gudnason H, Olofsson P, Dubiel M, Gudmundsson S (2005) Increased uterine artery vascular impedance is related to adverse outcome of pregnancy but is present in only one-third of late third-trimester pre-eclamptic women. Ultrasound Obstet Gynecol 25:459–463PubMedCrossRef
Liggins GC, Howie RN (1972) A controlled trial of antepartum glucocorticoid treatment for prevention of RDS in premature infants. Pediatrics 50:515–525PubMed
Lisonkova S, Joseph KS (2013) Incidence pf preeclampsia: risk factors and outcomes associeted with early- versus late-onset disease. Am J Obstet Gynecol 209:544.e1–544.e12CrossRef
Livingston JC, Livingston LW, Ramsey R et al (2003) Magnesium sulfate in women with mild preeclampsia: a randomised controlled trial. Obstet Gynecol 101:217–220PubMed
Lockwood CJ, Rand JH (1994) The immunbiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 49:432–441PubMedCrossRef
Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK et al (2009) Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol 49(3):242–246PubMedCrossRef
Lubarsky SL, Barton JR, Friedman SA, Nasreddine S, Ramadan MK, Sibai BM (1994) Late postpartum eclampsia revisted. Obstet Gynecol 83:502–505PubMedCrossRef
Lydakis C, Lip GJ, Beevers M, Beevers BG (1999) Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12:541–547PubMedCrossRef
Mabie WC, Gonzales AR, Sibai BM et al (1987) A comparative trial of labetalol und haydralacine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 70:328–333PubMed
Magann EF, Martin JN, Isaacs JD, Perry KG, Martin RW, Mey-drech EF (1993) Immediate postpartum curretage: accelerated recovery from severe preeclampsia. Obstet Gynecol 81:502–506PubMed
Magann EF, Bass D, Chauhan SP, Sullivan DL, Nartin RW, Martin JN (1994a) Disease stabilisation in patients with the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP). Am J Obstet Gynecol 171:1148–1153PubMedCrossRef
Magann EF, Perry KG, Meydrech EF, Harris RL, Chauhan SP, Martin JN (1994b) Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP). Am J Obstet Gynecol 171:1154–1158PubMedCrossRef
Magann EF, Bass D, Chauhan SO (1994c) Accelerated recovery from severe preeclampsia: uterine curettage versus nifedipine. J Soc Gynecol Investig 1:210–214PubMed
Magee LA, von Dadelszen P, Bohun CM et al (2003) Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study. J Obstet Gynaecol Can 2:372–382CrossRef
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, on behalf of the Canadian hypetensive disorders of pregnancy (HDP) working group (2014) Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 4:105–145PubMed
Magee LA, von Dadelszen P, Rey E et al (2015) Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 372(5):407–417PubMedCrossRef
Malin G, Bell SC, Waugh JJS (2007) Random albumin/creatinine ratio for quantification of proteinuria in manifest preeclampsia. Br J Obstet Gynaecol 114:118–119CrossRef
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A et al (2013) ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219PubMedCrossRef
Martin JN Jr (2013) Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia). Int J Gynecol Obstet 121:202–207CrossRef
Martin JN, Files JC, Blake PG, Norman PH, Martin RW, Hess WL, Morrison JC, Wiser WL (1990) Plasma exchange for preeclampsia I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. Am J Obstet Gynecol 162:126–137PubMedCrossRef
Martin JN Jr, Rinehart B, May WL et al (1999) The spectrum of severe preeclampsia: comparative analysis by HELLP syndrome classification. Am J Obstet Gynecol 180:1373–1384PubMedCrossRef
Martin JN, Rose CH, Briery CM (2006) Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 195:914–934PubMedCrossRef
Matchaba P, Moodley J (2004) Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst Rev CD 002076
Matsuo K, Kooshesh S, Dinc M, Sun CCJS, Kimura T, Baschat A (2007) Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 24:257–266PubMedCrossRef
McCarthy FP, Drewlo S, English FA, Kingdom J, Johns EJ, Walsh SK, Kenny LC (2011a) Evidence implicating peroxisome proliferator-activated receptor- γ in the pathogenesis of preeclampsia. Hypertension 58:882–887PubMedCrossRef
McCarthy FP, Drewlo S, Kingdom J, Johns EJ, Walsh SK, Kenny LC (2011b) Peroxisome proliferator-activated receptor- γ as a potential therapeutic target in the treatment of preeclampsia. Hypertension 58:280–286PubMedCrossRef
McGregor JA, Allen KG, Harris MA, Reese M, Wheeler M, French JI et al (2001) The omega-3 story: nutritional prevention of preterm birth and other adverse pregnancy outcome. Obstet Gynecol Surv 56(5 Suppl 1):S1–S13PubMedCrossRef
McMaster MT, Zhou J, Fisher SJ (2004) Abnormal placentation and the syndrome of preeclampsia. Semin Nephrol 24:540–547PubMedCrossRef
Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, Riet tre G et al (2008) Methods of prediction and prevention of pre-eclmapsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 12(6):iii–iv; 1–270CrossRef
Mello G, Parretti E, Fatini C, Riviello C, Genuini F et al (2005) Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 45:86–91PubMedCrossRef
Merchant SH, Mathew P, Vanderjagt TJ et al (2004) Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet Gynecol 103:1055–1058PubMedCrossRef
Michael CA (1979) Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol 8(Suppl 2):211–215CrossRef
Middeldorp S (2007) Thrombophilia and pregnancy, complications: cause or association? J Thromb Haemost 5:276–282PubMedCrossRef
Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL (1994) Preeclampsia and antioxidant nutritients: decreased plasma levels of reduced ascorbic acid, α-tocopherol, and β-carotene in women with preeclampsia. Am J Obstet Gynecol 171:150–157PubMedCrossRef
Minakami H, Morikawa M, Yamada T, Yamada T, Akaishi R, Nishida R (2014) Differentiation of acute fatty liver of pregnancy from syndrome of hemolysis, elevated liver enzymes and low platelet counts. J Obstet Gynaecol Res 40(3):641–649PubMedCrossRef
Miyakis S, Lockshin MD, Atsumi T, Branch DW et al (2006) International consensus statement on a update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306PubMedCrossRef
Montan S, Marzal K, Ingemarsson, NO S (1992) Randomised controlled trial of atenolol and pindolol in human pregancy: effects on fetal hemodynamics. BMJ 304:946–949PubMedPubMedCentralCrossRef
Moran P, Lindheimer MD, Davison JM (2004) The renal response to preeclampsia. Semin Nephrol 24:588–595PubMedCrossRef
Morris MC, Twickler DM, Hatab MR et al (1997) Cerebral blood flow and cranial magnetic resonance imaging in eclampsia and severe preeclampsia. Obstet Gynecol 89:561–568CrossRef
Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD (2012) Diagnostic accuracy of spot urinary protein and albumin to creatinin ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 9(345):e4342CrossRef
Mushambi MC, Halligan AW, Williamson K (1996) Recent developments in the pathophysiology and management of pre-eclampsia. Br J Anaesth 76:133–148PubMedCrossRef
National Institutes of Health (2000) Working group report on high blood pressure in pregnancy. National Institutes of Health, Washington DC
Ness RB, Roberts JM (1996) Heterogenous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 175:1365–1370PubMedCrossRef
North R, Ferrier C, Long D, Townend K, Kinkaid-Smith P (1994) Prevention of preeclampsia with prophylactic heparin and anti-platelet agents in women with underlying renal disease. Hypertens Pregnancy 13:135–144CrossRef
O´Brian E, Asmar R, Beilin L et al (2005) Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 23:697–701CrossRef
O’Brien JM, Barton JR (2005) Controversies with the diagnosis and management of HELLP syndrome. Clin Obstet Gynecol 46:460–477CrossRef
Odegard RA, Vatten LJ, Nilsen ST et al (2000) Preeclampsia and fetal growth. Obstet Gynecol 96:950–955PubMed
Odendaal HJ, Pattison RC, Bam R, Grove D, Kotze TJW (1990) Aggressive or expectant management for patients with severe preeclampsia between 28–34 weeks gestation: a randomized controlled trial. Obstet Gynecol 76:1070–1076PubMed
Olson S, Sacher NJ, Tabor A, Weber T, Walker JJ, Gland C (2000) Randomised clinical trials of fish oil supplementation in high-risk pregnancies. Br J Obstet Gynaecol 107:382–395CrossRef
Ounsted M (1988) The children of women who had hypertension during pregnancy. In: Rubin PC (Hrsg) Hypertension in pregnancy, Bd 10. Elsevier, Amsterdam, S 341–362
Papafragkakis H, Singhal S, Anand S (2013) Acute fatty liver in pregnancy. South Med J 106(10):588–593PubMedCrossRef
Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS (1993) Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 100:909–913PubMedCrossRef
Podymow T, August P (2008) Update on the use of antihypertensive drugs in pregnancy. Hypertension 51:960–969PubMedCrossRef
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH (2009) First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53:812–818PubMedCrossRef
Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH (2006) Vitamins in Pre-eclampsia (VIP) trial consortium. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367:1145–1154PubMedCrossRef
Raio L, Ghezzi F, Cromi A, Nelle M, Dürig P, Schneider H (2004) Sonographic jelly-like appearance of the placenta: a strong predictor of adverse pregnancy outcome. Prenat Diagn 24:182–188PubMedCrossRef
Rasmussen S, Irgens LM (2003) Fetal growth and body proportion in preeclampsia. Obstet Gynecol 101:575–583PubMed
Ray JG, Vermeulen MJ, Schull MJ, Redlmeier DA (2005) Cardiovascular health afte matenal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366:1797–1803PubMedCrossRef
Redman CWG (1991) Controlled trials of antihypertensive drugs in pregnancy. Am J Kidney Dis 17:149–154PubMedCrossRef
Redman CWG (1995) Hypertension in pregnancy. In: De Swiet M (Hrsg) Medical disorders in obstetric practice. Blackwell, Oxford, S 182–225
Redman CWG, Ounsted MK (1982) Safety for the child of drug treatment for hypertension in pregnancy. Lancet 1:1237PubMedCrossRef
Redman CWG, Sargent IL (2003) Pre-eclampsia, the placenta and the maternal systemic inflammatory response: a review. Placenta 24(Suppl A):S21–S27PubMedCrossRef
Redman CWG, Sargent IL (2009) Placental stress and preeclampsia: a revised view. Placenta 30(Suppl A):S38–S42, Trophoblast Research 23PubMedCrossRef
Redman CWG, Sacks GP, Sargent IL (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180:499–506PubMedCrossRef
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), ESC Committee for Practice Guidelines et al (2011) ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32(24):3147–3197PubMedCrossRef
Rey E, Couturier A (1994) The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 171:410–416PubMedCrossRef
Rey E, Garneau P, David M, Gauthier R, Leduc N et al (2009) Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 7:58–64PubMedCrossRef
Rimoldi FS, Scherrer U, Messerli FM. (2013) Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 23. doi:10.1093
Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E (2013) Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta – analysis. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol 41(5):491–499CrossRef
Roberts JM, Hubel CA (1999) Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet 354:788–789PubMedCrossRef
Rodger MA, Paidas M, McLintock C et al (2008) Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 112(2Pt1):320–324PubMedCrossRef
Rogue H, Paidas MJ, Funai EF et al (2004) Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 91:290–295
Rolfes D, Ishak K (1985) Acute fatty liver of pregnancy: a clinicopathologic study of 35 cases. Hepatology 5:1149–1158PubMedCrossRef
Ruffati A, Dalla Barba B, Del Ross T et al (1998) Outcome of fifty-five newborns of antiphospholipid antibody-postive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol 16:605–610
Rumbold A, Duley L, Crowther CA, Haslam RR (2008) Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 23(1), CD004227
Sattar N, Greer IA (2002) Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? Br Med J 325:157–160CrossRef
Saudan P, Brown MA, Buddle ML, Jones M (1998) Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 105:1177–1184PubMedCrossRef
Schlenzing C, Maurer S, Goppelt M, Ulm K, Kolben M (2000) Postpartum curettage in patients with HELLP-Syndrome does not result in accelerated recovery. Eur J Obstet Gynecol Biol Reprod 91:25–28CrossRef
Sergio F, Maria Clara D, Gabriella F et al (2006) Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 25:115–162PubMedCrossRef
Shekhar S, Sharma C, Thakur S, Verma S (2013) Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol 122(5):1057–1063PubMedCrossRef
Shojaati K, Causevic M, Kadereit B et al (2004) Evidence for compromised aldosterone synthase enzyme activity in preeclampsia. Kidney Int 66:2322–2328PubMedCrossRef
Sibai BM (1996) Treatment of hypertension in pregnant women. N Engl J Med 335:275–265CrossRef
Sibai BM (2003) Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 102:181–192PubMed
Sibai BM (2004a) Diagnosis, controversies and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 103:981–991PubMedCrossRef
Sibai BM (2004b) Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 190:1520–1526PubMedCrossRef
Sibai BM (2005) Diagnosis, prevention and management of preeclampsia. Obstet Gynecol 105:402–410PubMedCrossRef
Sibai BM, Stella CL (2009) Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 200:481.e1–481.e7CrossRef
Sibai BM, Abdella TN, Spinnato JA, Anderson GD (1986) Eclampsia V. The incidence of nonpreventable eclampsia. Am J Obstet Gynecol 154:581–586PubMedCrossRef
Sibai BM, Mercer B, Sarinoglu C (1991) Severe preeclampsia in the second trimester: recurrence risk and long term prognosis. Am J Obstet Gynecol 165:1408–1412PubMedCrossRef
Sibai BM, Barton JR, Akl S et al (1992) A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 167:879–884PubMedCrossRef
Sibai BM, Ramadan MK, Usta I et al (1993) Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169:1000–1006PubMedCrossRef
Sibai BM, Mercer BM, Schiff E, Friedman SA (1994) Aggressive versus expectant management of severe preeclampsia at 28–32 weeks gestation. Am J Obstet Gynecol 171:818–822PubMedCrossRef
Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O et al (2012) Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 7(11):e50208PubMedPubMedCentralCrossRef
Simon J, Gray A, Duley L, Magpie Trial Collaborative Group (2006) Cost-effectiveness of phrophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG 113(2):144–151PubMedCrossRef
Smulian JC, Anath CV, Vinzileos AM, Knuppel RA (2002) Fetal deaths in the United States. Influence of high-risk conditions and implications for management. Obstet Gynecol 100:1183–1189PubMed
Smith GC (2001) Life-table analysis of the rate of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol 184:489–496PubMedCrossRef
Smith NA, Lyons JG, McElrath TF (2010) Protein:creatinine ratio in uncomplicated twin pregnancy. Am J Obstet Gynecol 203(381):e1–e4
Snyder SW, Cardwell MS (1989) Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol 161:35–36PubMedCrossRef
Spinnato JA II, Freire S, Pinto e Silav JL, Cunha Rudge MV, Martins-Costa S, Koch MA et al (2007) Antioxidant therapy to prevent preeclampsia: a randomised controlled trial. Obstet Gynecol 110:1311–1318PubMedCrossRef
Steiner M (1989) Aktuelle Bilanz der mütterlichen Mortalität. In: Hillemanns HG, Schillinger H (Hrsg) Das Restrisiko gegenwärtiger Geburtshilfe. Springer, Berlin, S 17–S 23CrossRef
Stepan H, Jank A (2009) Angiogene Faktoren und ihre Rolle in der Entstehung und Vorhersage der Präeklampsie. Z Geburtshilfe Neonatol 213(3):101–105PubMedCrossRef
Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198(2):175.e1–175 e6CrossRef
Stern C, Trapp EM, Mautner E, Lang U, Vervar-Zivkovic M (2013) The impact of severe preeclampsia on maternal quality of life. Qual Life Res. doi:10.1007/s11136-013-0525-3PubMed
Subtil D, Goeusse P, Houfflein-Deborge V et al (2003a) Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women, pt 2. BJOG 110:485–491PubMed
Subtil D, Goeusse P, Puech F et al (2003b) Aspririn (100 mg) used for prevention of preeclampsia in nulliparous women, pt 1. BJOG 110:475–484PubMed
Talledo OE (1966) Renin-angiotensin system in normal and toxemic pregnancies. I. Angiotensininfusion test. Am J Obstet Gynecol 96:141–143PubMed
Thadhani R, Kistner T, Hagman H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T (2011) Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124:940–950PubMedCrossRef
Thangaratinam S, Ismail KMK, Shap S, Coomarasany A, Khan KS (2006) Accuracy of serum uric acid in predicting complications of preeclampsia: a systemic review. Br J Obstet Gynaecol 113:369–378CrossRef
Thangaratinam S, Coomarasany A, O’Mahony F, Sharp S et al (2009) Estimation of proteinuria as a predictor of complications of pre-eclmapisa: a systematic review. BMC Med 7:1–9CrossRef
The Magpie Trial (2002) Do women with preeclampsia, and their babies, benefit from magnesium sulfate? A randomised placebo-controlled trial. Lancet 359:1877–1890CrossRef
Towers CV, Piron RA, Nageotte MP et al (1993) Cocain intoxication presenting as preeclampsia and eclampsia. Obstet Gynecol 81:545–547PubMed
Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM (2013) The definition of severe early –onset preeclampsia. Statements from the international society fort he study of hypertension in pregnancy (ISSHP). Pregnancy Hypertens 3:44–47PubMed
Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA (2014) The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Hypertens Pregnancy 4:97–104
Triche EW, Uzun A, DeWan AT, Kurihara I, Liu J, Occhiogrosso R, Shen B, Parker J, Padbury JF (2014) Bioinformatic approach to the genetics of preeclampsia. Obstet Gynecol 123(6):1155–1161PubMedPubMedCentralCrossRef
Tuffnell DJ, Lilford RJ, Buchanan PC (1992) Randomised controlled trial of daycare for hypertension in pregnancy. Lancet 339:224–227PubMedCrossRef
Tuffnell DJ, Jankowicz D, Lindow SW, Lyons G, Mason GC, Russel IF, Walker JJ (2005) Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. Br J Obstet Gynaecol 112:875–880CrossRef
Uzan S, Beaufils M, Breart G, Bazic B, Capitant C, Paris J (1991) Prevention of fetal growth retardation with low dose aspirin: findings of the EPREDAL trial. Lancet 337:1427–1431PubMedCrossRef
Van Wijk MJ, Nieuwland R, Boer K et al (2002) Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 187:450–456CrossRef
Varner M, Rinderknecht NK (1980) Acute fatty metamorphosis of pregnancy. A maternal mortality and literature review. J Reprod Med 24(4):177–180PubMed
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12(6):642–649PubMedCrossRef
Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202(2):161.e1–161.e11CrossRef
Vetter K, Kilavuz Ö (1999) Dopplersonografie und Präeklampsie. Gynakologe 10:761–767
Vikse BE, Irgens LM, Leivestad T, Skjaerven RS, Iversen BM (2008) Preeclampsia and the risk of end-stage renal disease. N Engl J Med 359:800–809PubMedCrossRef
Villar J, Abalos B, Nardin JM et al (2004) Strategies to prevent and treat preeclampsia: evidence fromrandomized controlled trials. Semin Nephrol 24:607–615PubMedCrossRef
Villar J, Purvar M, Merialdi M, Zavaleta N, Tien NN, Anthony J (2007) WHO randomised trial of vitamine C & E supplementation among women at high risk for preeclampsia and nutritional deficiency. Am J Obstet Gynecol 197:S4CrossRef
Vink GJ, Moodley J (1982) The effect of low-dose dihydralazine on the fetus in the emergency treatment of hypertension in pregnancy. S Afr Med J 62:475–477PubMed
Visser W, Wallenburg HCS (1995a) Temporising management of severe preeclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 102:111–117PubMedCrossRef
Visser W, Wallenburg ACS (1995b) Maternal and perinatal outcome of temporizing menagement in 254 consecutive patients with severe preeclampsia remote from term. Eur J Obstet Gynecol Reprod Biol 63:147–153PubMedCrossRef
von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA (2000) Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a metaanalysis. Lancet 355:87–92CrossRef
Waismann GD, Mayorga L, Camer MI, Vignolo CA, Martinotti A (1988) Magnesium plus nifedipin: potentiation of hypotensive effects in preeclampsia? Am J Obstet Gynecol 159:308–309CrossRef
Waugh JJ, Clark TJ, Divakaran TG et al (2004) Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy. Obstet Gynecol 103:769–777PubMedCrossRef
Wei Q, Zhang L, Liu X (2010) Clinical diagnosis and treatment of acute fatty liver of pregnancy: a literature review and 11 new cases. J Obstet Gynaecol Res 36(4):751–756PubMedCrossRef
Welsch H, Krone HA (1994) Mütterliche Mortalität und HELLP-Syndrom in Bayern 1982–1992. Zentralbl Gynakol 116:202–206PubMed
Wikström AK, Haglund B, Olovsson M, Lindenberg SN (2005) The risk of maternal heart disease after gestational hypertensive disease. Br J Obstet Gynaecol 112:1486–1491CrossRef
Williams MA, Zingheim RW, Kind IB, Zebelman AM (1995) Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia. Epidemiology 6:232–237PubMedCrossRef
Wilson WA, Gharavi AE, Koike T et al (1999) International Consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef
Wilton A, de Greef A, Shennan A (2007) Rapid assessment of blood pressure in the obstetric day unit using Microlife MaM technology. Hypertens Pregnancy 26:31–37PubMedCrossRef
Xuong XY, Wang FL, Davidge ST et al (2000) Maternal smoking and preeclampsia. J Reprod Med 45:727
Zeeman GG, Fleckenstein JL, Twickler DM, Cunningham FG (2004) Cerebral infarction in eclampsia. Am J Obstet Gynecol 190:714–720PubMedCrossRef
Zhang J, Meikle S, Trumble A (2003) Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 22(2):203–212PubMedCrossRef
Metadaten
Titel
Hypertensive Schwangerschaftserkrankungen
verfasst von
Luigi Raio
Marc Baumann
Henning Schneider
Copyright-Jahr
2016
Verlag
Springer Berlin Heidelberg
Buch
Die Geburtshilfe

Print ISBN: 978-3-662-45063-5

Electronic ISBN: 978-3-662-45064-2

Copyright-Jahr: 2016

DOI
https://doi.org/10.1007/978-3-662-45064-2_22